Search results
Author(s):
Raymond B Fohtung
,
Michael W Rich
Added:
3 years ago
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, with an overall prevalence of approximately 1 % in the general population.1 An estimated 2.3 million adults in the US have AF, and this number is projected to increase to 5.6 million by 2050.1 The most clinically important complication from AF lies in the risk for cardiac thrombus formation and systemic embolism…
View more
Author(s):
Rami Khayat
,
Andrew Pederzoli
,
William T Abraham
Added:
3 years ago
Heart failure is the only cardiovascular disease with increasing incidence and mortality.1 Approximately five million Americans have heart failure, with an annual incidence of 10 per 1,000 in individuals over 65 years of age, an already rising demographic segment of society. Heart failure is the most frequent Medicare diagnosis, with most of its cost related to hospitalizations.1,2 Identification…
View more
Author(s):
Ana Mola
,
Carmen Perez-Terzic
,
Randal Thomas
,
et al
Added:
3 years ago
The changing population landscape in the US has impacted the many levels of the US healthcare system. It is estimated that, by 2050, minority populations together will comprise approximately 50% of the total population.1 This demographic shift has prompted policy makers, scientists, researchers, educators, and healthcare providers to draft a series of national health initiatives to define,…
View more
Author(s):
Steven R Sigman
Added:
3 years ago
Although less common than other forms of cardiomyopathy, cardiac sarcoidosis (CS), both as part of a systemic process and in its isolated form, is an important, and increasingly recognized disorder. This is felt to be due, in part, to advances in cardiac imaging and heightened awareness of the disorder.1,2 CS is associated with high rates of morbidity and mortality, including sudden cardiac death…
View more
Cardiac Toxicity of Cancer Chemotherapy
Author(s):
Aarti Asnani
Start date:
Aug 08, 2017
Broadcast
Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy
Author(s):
Donald E Cutlip
Added:
3 years ago
Article
Author(s):
Kevin Lee
,
Iva Minga
,
Eryn Cameron
,
et al
Added:
9 months ago
Added:
5 years ago
BAROSTIM THERAPY for RHTN Physician Testimonial
View more
Author(s):
Iosif Xenogiannis
,
Charalampos Varlamos
,
Despoina-Rafailia Benetou
,
et al
Added:
2 years ago